Timothy R. O'Connor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Timothy R. O'Connor has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Roberto Gutierrez
Department of Cancer Biology, Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute at the City of Hope, Duarte, California, USA
3 shared publicationsStephanie L. Nay
3 shared publicationsSteven E. Bates
Biology Division, City of Hope National Medical Center, 1450 East Duarte Road, Duarte, CA 91010
3 shared publicationsDong-Hyun Lee
Department of Biological Sciences, College of Natural Sciences, Chonnam National University, Gwangju, South Korea
2 shared publicationsAlana Battad
Department of Diabetes and Cancer Metabolism, Beckman Research Institute at the City of Hope, Duarte, California, USA
1 shared publicationAlya Ahmad
1 shared publication
Latest Publications
- Open Access
- 24 June 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (8) , 107492
Lack of mismatch repair enhances resistance to methylating agents for cells deficient in oxidative demethylation
- 24 June 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (8) , 107492
Open AccessLack of mismatch repair enhances resistance to methylating agents for cells deficient in oxidative demethylation
- Open Access
In vitro determinants of e-cig aerosol condensate bioavailability and toxicity: Influence of cell culture parameters and utility of a normalized dose metric in e-cigarette studies
Electronic cigarettes (e-cigs) have a strong foothold in the marketplace as a product to replace tobacco cigarette usage. Despite many researchers investigating the use of e-cigs and possible health issues, there is still controversy concerning how to evaluate and use e-cig condensates. Therefore, to identify factors that influence in vitro e-cig studies, we examined parameters that can impact experimental outcomes. We generated high wattage e-cig aerosol condensate (ECAC) to determine reproducible conditions to evaluate ECAC with respect to cellular survival. Cytotoxicity of ECAC was independent of serum conditions. However, cytotoxicity of ECAC is altered by treatment duration and by physical factors, including cell seeding density and volume of ECAC used. In addition, interactions between ECAC components and cells, as well as the culture vessel surface, diminish the bioavailability of ECAC components in vitro and altered the results obtained. Moreover, the cell seeding density changes reactive oxygen species production in response to ECAC exposure. Our data indicated that normalized ECAC doses (ECAC weight per cell) better reflect the toxicity of ECAC than nominal doses (ECAC percentage). These results provide factors for researchers to consider in the design of in vitro experiments using ECAC.
Open AccessIn vitro determinants of e-cig aerosol condensate bioavailability and toxicity: Influence of cell culture parameters and utility of a normalized dose metric in e-cigarette studies
Electronic cigarettes (e-cigs) have a strong foothold in the marketplace as a product to replace tobacco cigarette usage. Despite many researchers investigating the use of e-cigs and possible health issues, there is still controversy concerning how to evaluate and use e-cig condensates. Therefore, to identify factors that influence in vitro e-cig studies, we examined parameters that can impact experimental outcomes. We generated high wattage e-cig aerosol condensate (ECAC) to determine reproducible conditions to evaluate ECAC with respect to cellular survival. Cytotoxicity of ECAC was independent of serum conditions. However, cytotoxicity of ECAC is altered by treatment duration and by physical factors, including cell seeding density and volume of ECAC used. In addition, interactions between ECAC components and cells, as well as the culture vessel surface, diminish the bioavailability of ECAC components in vitro and altered the results obtained. Moreover, the cell seeding density changes reactive oxygen species production in response to ECAC exposure. Our data indicated that normalized ECAC doses (ECAC weight per cell) better reflect the toxicity of ECAC than nominal doses (ECAC percentage). These results provide factors for researchers to consider in the design of in vitro experiments using ECAC.
- Open Access
- 1 January 2021
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 4 (2) , 414-423
DNA direct reversal repair and alkylating agent drug resistance
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.
- 1 January 2021
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 4 (2) , 414-423
Open AccessDNA direct reversal repair and alkylating agent drug resistance
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.
- Open Access
- 1 January 2018
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Medical Science
- Vol. 5 (3) , 284-302
DNA direct repair pathways in cancer
DNA direct repair (DR) pathways are unique in DNA repair because those mechanisms restore the genetic information without any DNA synthesis and are thus error free. We review the DR mechanisms, consequences of the absence of those systems in cells, their occurrence in cancer, regulation of their genes and proteins in cancer cells, and the potential exploitation of inhibitors to enhance chemotherapy.
- 1 January 2018
- Published by American Institute of Mathematical Sciences (AIMS) in AIMS Medical Science
- Vol. 5 (3) , 284-302
Open AccessDNA direct repair pathways in cancer
DNA direct repair (DR) pathways are unique in DNA repair because those mechanisms restore the genetic information without any DNA synthesis and are thus error free. We review the DR mechanisms, consequences of the absence of those systems in cells, their occurrence in cancer, regulation of their genes and proteins in cancer cells, and the potential exploitation of inhibitors to enhance chemotherapy.
- Open Access
- 18 November 2015
- Published by IntechOpen
Direct Reversal Repair in Mammalian Cells
Direct Reversal Repair in Mammalian Cells | InTechOpen, Published on: 2015-11-18. Authors: Alya Ahmad, Stephanie L. Nay and Timothy R. O’Connor
- 18 November 2015
- Published by IntechOpen
Open AccessDirect Reversal Repair in Mammalian Cells
Direct Reversal Repair in Mammalian Cells | InTechOpen, Published on: 2015-11-18. Authors: Alya Ahmad, Stephanie L. Nay and Timothy R. O’Connor
- Open Access
- 1 September 2012
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 11 (9) , 1948-1958
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Individuals with an inherited BRCA1 or BRCA2 mutation have an elevated risk of developing breast cancer. The resulting tumors typically lack homologous recombination repair as do a subset of sporadic tumors with acquired BRCA deficiency. Clinical responses to monotherapy with platinum drugs or poly PARP inhibitors (PARPi) have been shown for BRCA-associated cancers. However, there are limited data on combination therapy with PARPi and platinum drugs, the mechanism of action of this combination, and the role of BRCA1 or BRCA2 in chemosensitivity. We compared the efficacy of ABT-888 (a PARPi) with that of cisplatin or carboplatin (platinum drugs) alone or in combinations by examining the survival of treated Brca-proficient and -deficient mouse embryonic stem cells. In addition, drug-induced growth inhibition of a BRCA1 and a BRCA2 null cell line were compared with their isogenic BRCA-complemented lines. Although each monotherapy killed or inhibited proliferation of Brca/BRCA-deficient cells, an enhanced effect was observed after treatment with ABT-888 in combination with carboplatin. Moreover, the ABT-888/carboplatin combination delayed tumor growth in Brca2 xenografts. The drugs caused DNA damage and apoptosis. Along with greater PARP activity in Brca/BRCA-deficient cells, these effects correlated with increased chemosensitivity. Our data suggest that ABT-888 and carboplatin combination treatment will be more successful than monotherapy in addressing many BRCA-associated cancers. A randomized phase II trial has recently been initiated to test this hypothesis to assist in the discovery of more effective therapies for patients with BRCA. Mol Cancer Ther; 11(9); 1948–58. ©2012 AACR.
- 1 September 2012
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 11 (9) , 1948-1958
Open AccessEnhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Individuals with an inherited BRCA1 or BRCA2 mutation have an elevated risk of developing breast cancer. The resulting tumors typically lack homologous recombination repair as do a subset of sporadic tumors with acquired BRCA deficiency. Clinical responses to monotherapy with platinum drugs or poly PARP inhibitors (PARPi) have been shown for BRCA-associated cancers. However, there are limited data on combination therapy with PARPi and platinum drugs, the mechanism of action of this combination, and the role of BRCA1 or BRCA2 in chemosensitivity. We compared the efficacy of ABT-888 (a PARPi) with that of cisplatin or carboplatin (platinum drugs) alone or in combinations by examining the survival of treated Brca-proficient and -deficient mouse embryonic stem cells. In addition, drug-induced growth inhibition of a BRCA1 and a BRCA2 null cell line were compared with their isogenic BRCA-complemented lines. Although each monotherapy killed or inhibited proliferation of Brca/BRCA-deficient cells, an enhanced effect was observed after treatment with ABT-888 in combination with carboplatin. Moreover, the ABT-888/carboplatin combination delayed tumor growth in Brca2 xenografts. The drugs caused DNA damage and apoptosis. Along with greater PARP activity in Brca/BRCA-deficient cells, these effects correlated with increased chemosensitivity. Our data suggest that ABT-888 and carboplatin combination treatment will be more successful than monotherapy in addressing many BRCA-associated cancers. A randomized phase II trial has recently been initiated to test this hypothesis to assist in the discovery of more effective therapies for patients with BRCA. Mol Cancer Ther; 11(9); 1948–58. ©2012 AACR.
- 1 May 2012
- Published by Elsevier in DNA Repair
- Vol. 11 (5) , 502-510
Alkbh2 protects against lethality and mutation in primary mouse embryonic fibroblasts
- 1 May 2012
- Published by Elsevier in DNA Repair
- Vol. 11 (5) , 502-510
Alkbh2 protects against lethality and mutation in primary mouse embryonic fibroblasts
- Open Access
- 6 March 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (3) , e30541
DNA Repair in Human Pluripotent Stem Cells Is Distinct from That in Non-Pluripotent Human Cells
The potential for human disease treatment using human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells (iPSCs), also carries the risk of added genomic instability. Genomic instability is most often linked to DNA repair deficiencies, which indicates that screening/characterization of possible repair deficiencies in pluripotent human stem cells should be a necessary step prior to their clinical and research use. In this study, a comparison of DNA repair pathways in pluripotent cells, as compared to those in non-pluripotent cells, demonstrated that DNA repair capacities of pluripotent cell lines were more heterogeneous than those of differentiated lines examined and were generally greater. Although pluripotent cells had high DNA repair capacities for nucleotide excision repair, we show that ultraviolet radiation at low fluxes induced an apoptotic response in these cells, while differentiated cells lacked response to this stimulus, and note that pluripotent cells had a similar apoptotic response to alkylating agent damage. This sensitivity of pluripotent cells to damage is notable since viable pluripotent cells exhibit less ultraviolet light-induced DNA damage than do differentiated cells that receive the same flux. In addition, the importance of screening pluripotent cells for DNA repair defects was highlighted by an iPSC line that demonstrated a normal spectral karyotype, but showed both microsatellite instability and reduced DNA repair capacities in three out of four DNA repair pathways examined. Together, these results demonstrate a need to evaluate DNA repair capacities in pluripotent cell lines, in order to characterize their genomic stability, prior to their pre-clinical and clinical use.
- 6 March 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (3) , e30541
Open AccessDNA Repair in Human Pluripotent Stem Cells Is Distinct from That in Non-Pluripotent Human Cells
The potential for human disease treatment using human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells (iPSCs), also carries the risk of added genomic instability. Genomic instability is most often linked to DNA repair deficiencies, which indicates that screening/characterization of possible repair deficiencies in pluripotent human stem cells should be a necessary step prior to their clinical and research use. In this study, a comparison of DNA repair pathways in pluripotent cells, as compared to those in non-pluripotent cells, demonstrated that DNA repair capacities of pluripotent cell lines were more heterogeneous than those of differentiated lines examined and were generally greater. Although pluripotent cells had high DNA repair capacities for nucleotide excision repair, we show that ultraviolet radiation at low fluxes induced an apoptotic response in these cells, while differentiated cells lacked response to this stimulus, and note that pluripotent cells had a similar apoptotic response to alkylating agent damage. This sensitivity of pluripotent cells to damage is notable since viable pluripotent cells exhibit less ultraviolet light-induced DNA damage than do differentiated cells that receive the same flux. In addition, the importance of screening pluripotent cells for DNA repair defects was highlighted by an iPSC line that demonstrated a normal spectral karyotype, but showed both microsatellite instability and reduced DNA repair capacities in three out of four DNA repair pathways examined. Together, these results demonstrate a need to evaluate DNA repair capacities in pluripotent cell lines, in order to characterize their genomic stability, prior to their pre-clinical and clinical use.
- Open Access
- 24 November 2009
- Published by Wiley in Biochemistry and Molecular Biology Education
- Vol. 37 (6) , 344-348
Algorithm for writing a scientific manuscript
We present an algorithm for the construction of a strong initial draft. It is designed to overcome writer's block and to assist scientists who are not native English speakers. The writing starts with making figures and tables. These suggest several terse summary statements, the few major conclusions or observations the author will present to the scientific community. After identification of the audience, the specific community addressed, materials and methods are written to explain how the tables and figures were generated. Results are initially restricted to describing the logical data relations in each table and figure. The discussion then converts each data relationship into mechanistic cause‐and‐effect interpretations suitable for the A brief epilogue deals with the submission and the fate of the final manuscript once submitted. Although other models for the initial draft exist, this model has worked for us and new researchers in our laboratories and addresses problems we encountered while editing manuscripts.
- 24 November 2009
- Published by Wiley in Biochemistry and Molecular Biology Education
- Vol. 37 (6) , 344-348
Open AccessAlgorithm for writing a scientific manuscript
We present an algorithm for the construction of a strong initial draft. It is designed to overcome writer's block and to assist scientists who are not native English speakers. The writing starts with making figures and tables. These suggest several terse summary statements, the few major conclusions or observations the author will present to the scientific community. After identification of the audience, the specific community addressed, materials and methods are written to explain how the tables and figures were generated. Results are initially restricted to describing the logical data relations in each table and figure. The discussion then converts each data relationship into mechanistic cause‐and‐effect interpretations suitable for the A brief epilogue deals with the submission and the fate of the final manuscript once submitted. Although other models for the initial draft exist, this model has worked for us and new researchers in our laboratories and addresses problems we encountered while editing manuscripts.
- 15 June 2007
- Published by Elsevier in Analytical Biochemistry
- Vol. 365 (2) , 246-259
Monitoring repair of DNA damage in cell lines and human peripheral blood mononuclear cells
- 15 June 2007
- Published by Elsevier in Analytical Biochemistry
- Vol. 365 (2) , 246-259
Monitoring repair of DNA damage in cell lines and human peripheral blood mononuclear cells